METHOD FOR STAGING CARDIAC AUTONOMIC NEUROPATHY REGARDLESS OF ITS CLINICAL MANIFESTATIONS IN PATIENTS WITH METABOLIC SYNDROME Russian patent published in 2024 - IPC A61B5/352 A61B5/329 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology, endocrinology and neurology. Background study of heart rate variability is carried out in a lying position for 5 minutes and when an active orthostatic test is performed for 5 minutes, followed by spectral analysis and calculation of relative spectral values representing the contribution of each of the components of the heart rate oscillation spectrum: VLF – very low-frequency, LF – low-frequency in total power of spectrum of rhythm oscillations. Ratio of each relative value during the orthostatic test to that during the background recording is calculated. In patients with metabolic syndrome with simultaneous value of ratio %VLF_{orthostatic test}/%VLF_background more than 1.0 and value of ratio %LF_{orthostatic test}/%LF_background 0.99–0.80, stage 1 of CAN is determined; with simultaneous value of ratio %VLF_{orthostatic test}/%VLF_background more than 1.0 and value of ratio %LF_{orthostatic test}/%LF_background 0.79–0.50, stage 2 of CAN is determined; with simultaneous value of ratio %VLF_{orthostatic test}/%VLF_background more than 1.0 and value of ratio %LF_{orthostatic test}/%LF_background less than 0.49, stage 3 of CAN is determined; and with simultaneous value of ratio %VLF_{orthostatic test}/%VLF_background less than 1.0 and value of ratio %LF_{orthostatic test}/%LF_background less than 1.0, atypical stage of CAN is determined.

EFFECT: method provides staging cardiac autonomic neuropathy regardless of the presence of its clinical manifestations in patients with metabolic syndrome, which will allow prescribing the pathogenetically determined therapy in a timely manner to prevent the progression of the disease and reduce the risk of fatal complications.

1 cl, 5 tbl, 4 ex